A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
Eligible age
12+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety, tolerability, biological activity, and initial efficacy of PM577a, an investigational Prime Editing therapy, in adults and adolescents with Wilson disease (WD). Wilson disease is caused by changes (mutations) in the ATP7B gene that prevent the body from removing excess copper normally. PM577a is designed to precisely correct one of the most common disease-causing ATP7B mutations (p.H1069Q) in liver cells with the goal of restoring normal copper metabolism. This is the first study of PM577a in people. Participants will receive a single intravenous (IV) infusion of PM577a and will be monitored closely to evaluate safety, how the body responds to treatment, whether copper metabolism improves, and whether treatment may improve signs and symptoms of Wilson disease.
Sponsor: Prime Medicine, Inc.
You may qualify if…
- ✓ Confirmed Wilson Disease (WD) diagnosis as determined by medical history consistent with WD
- ✓ Historical genetic analysis demonstrating biallelic pathogenic, likely pathogenic, or suspected pathogenic ATP7B variants, including at least one p.H1069Q allele.
- ✓ Treated and stable on standard of care therapy for WD for the past 6 months prior to signing ICF, as documented by a history of adherence to SOC medications (i.e., penicillamine, trientine, and/or zinc) without significant medication or dose/frequency changes, per Investigator judgement.
- ✓ Demonstrated Adequate Copper Control confirmed at screening
- ✓ Willingness to maintain a stable, copper-conscious diet and avoid copper-containing supplements, from signing of the ICF until the physician determines that it is no longer necessary post-infusion.
- ✓ Willingness to abstain from alcohol use from start of the screening period through 3 months after PM577a infusion and adhere to recommendations of moderate alcohol consumption (as defined in this protocol) through primary follow-up period.
- ✓ Participants are expected to enroll in a separate long-term follow-up study for a total of approximately 15 years of follow-up following PM577a administration.
You may not qualify if…
- ✕ Known prior medically significant reactions (e.g., severe hypersensitivity, myocarditis) to an LNP-based or PEG-containing product (e.g., mRNA-based COVID vaccinations, MiraLAX) or any medication required as part of the clinical study protocol
- ✕ Receipt of any prior gene therapy for WD, including AAV-based therapy
- ✕ Receipt of any liver-directed LNP gene therapy (including siRNA or ASO therapies) or gene editing treatment.
- ✕ Unstable neurological conditions within the prior 12 months which may impact participant safety or participation in the study, including ability to complete study requirements or procedures as outlined in the clinical study protocol in the opinion of the Investigator
- ✕ In individuals with psychiatric involvement, current or fluctuant clinical instability with new or changing diagnoses or substantial medication regimen changes in the past 12 months that could limit their participation, in the opinion of the Investigator.
- ✕ Receipt of prior liver transplantation or listed for transplantation
- ✕ Body Mass Index ≥ 35 kg/m2
- ✕ Evidence of Severe Hepatic Impairment or uncontrolled liver disease within 6 months before screening.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07748403 · last updated 2026-10-01